Traders should watch for closing conditions including Theravance shareholder vote and regulatory approvals, expected in H2 2026. The accretive nature and non-dilutive financing suggest potential upside; monitor YUPELRI sales trends and the $100M milestone in Q1 2027.
ZYME drugs
ZYME drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 29 $24.10entry
- T+1 · 5mo ago +8.46%α +7.69% · $26.14
- T+5 · 4mo ago +5.10%α +3.72% · $25.33
- T+20 · 4mo ago −5.15%α −4.87% · $22.86
- T+60 · 8w ago +14.38%α +9.99% · $27.57
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Zymeworks Inc. (ZYME) announced an agreement to acquire Theravance Biopharma (TBPH) for $17.00 per share, or approximately $929 million in total cash consideration. The acquisition adds YUPELRI® (revefenacin), the first and only approved nebulized LAMA for COPD maintenance treatment, which generated ~$60 million in annualized cash flow. The deal is financed via a $350 million non-recourse note from OMERS Life Sciences, $219 million of Zymeworks' cash, and Theravance's ~$360 million expected net cash, with an expected $100 million TRELEGY milestone in Q1 2027 reducing net investment. The transaction is expected to be accretive to earnings and cash flow upon closing in H2 2026.
Key Financial Metrics
Key Facts
- Total transaction value: ~$929 million cash consideration at $17.00 per share.
- YUPELRI® net sales: $266.6M in 2025 (12% YoY growth), $62.4M in Q1 2026 (7% growth).
- Financing: $350M non-recourse note from OMERS Life Sciences; $219M Zymeworks cash; Theravance expected net cash ~$360M.
- Expected $100M TRELEGY milestone from Royalty Pharma in Q1 2027.
- Share repurchase program of up to $125M authorized; $35.4M spent to date.
- Closing expected in H2 2026, subject to shareholder and regulatory approvals.
Financial Impact
Transaction value ~$929M; effective net investment reduced by roughly 50% after $100M milestone. Accretive to earnings and cash flow.
Risk Factors
- Failure to obtain shareholder or regulatory approval.
- Integration risks and potential decline in YUPELRI sales growth.
- Generic entry risk (licensed April 2039 but could be earlier).
- Execution risk on restructuring and cost synergies.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3318760 |
Track record
25 reports on ZYME
6 of 8 bullish or bearish reports moved the stock their way by T+20. Best: +16.72% at T+60 after the Jun 14, 2026 report. 8 of 10 went positive at some point.
Filters
- Nov 16, 2026today 8-K Neutral 4/10 Entry price pending
- Nov 16, 2026today Press Release Neutral 4/10 Entry price pending
- Nov 13, 20263d ago 144 Neutral 2/10 Entry $26.24 Now $26.24 −0.00% settles Dec 14
- Nov 9, 20267d ago 8-K/A Neutral 5/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 9, 20267d ago Press Release Bullish 6/10 Entry $31.46 Now $26.24 −16.59% settles Dec 9
- Nov 3, 202613d ago Institutional Cluster Neutral 2/10 Entry $30.94 Now $26.24 −15.19% settles Dec 3
- Oct 26, 202621d ago DEFA14A Neutral 2/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 26, 202621d ago DEF 14A Neutral 3/10 Entry $28.85 Now $26.24 −9.05% settles Nov 24
- Oct 23, 202624d ago 8-K Bullish 7/10 Entry $28.22 Now $26.24 −7.02% settles Nov 20
- Oct 15, 20264w ago Press Release Neutral 1/10 Entry $25.75 to $29.07 Now $26.24 +1.90% ▲ +12.89% +14.31% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers